

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2003 MAINE

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | Number of Beneficiaries | | | | | | | Number of Benefit Months | | | | | | |
|--|-------------------------|--------------|---------------|---------------|----------------|-------------------|--|--------------------------|---------------|----------------|----------------|------------------|-------------------|--|
| | All | Aged | Disabled | Adults | Children | Other/ Unknown | | All | Aged | Disabled | Adults | Children | Other/ Unknown | |
| All | 234,274 | 1,463 | 24,393 | 91,781 | 116,637 | 0 | | 2,271,879 | 10,130 | 268,695 | 828,904 | 1,164,150 | 0 | |
| Age | | | | | | | | | | | | | | |
| 5 and younger | 37,670 | 0 | 782 | 0 | 36,888 | 0 | | 361,709 | 0 | 8,132 | 0 | 353,577 | 0 | |
| 6-14 | 53,094 | 0 | 3,091 | 3 | 50,000 | 0 | | 553,316 | 0 | 34,486 | 22 | 518,808 | 0 | |
| 15-20 | 32,991 | 0 | 2,446 | 868 | 29,677 | 0 | | 325,132 | 0 | 26,778 | 7,158 | 291,196 | 0 | |
| 21-44 | 84,040 | 17 | 8,420 | 75,539 | 64 | 0 | | 783,461 | 136 | 93,893 | 688,927 | 505 | 0 | |
| 45-64 | 25,120 | 101 | 9,654 | 15,358 | 7 | 0 | | 239,043 | 897 | 105,406 | 132,688 | 52 | 0 | |
| 65-74 | 506 | 493 | 0 | 13 | 0 | 0 | | 4,345 | 4,236 | 0 | 109 | 0 | 0 | |
| 75-84 | 420 | 420 | 0 | 0 | 0 | 0 | | 2,693 | 2,693 | 0 | 0 | 0 | 0 | |
| 85 and older | 432 | 432 | 0 | 0 | 0 | 0 | | 2,168 | 2,168 | 0 | 0 | 0 | 0 | |
| Unknown | 1 | 0 | 0 | 0 | 1 | 0 | | 12 | 0 | 0 | 0 | 12 | 0 | |
| Gender | | | | | | | | | | | | | | |
| Female | 127,235 | 970 | 12,814 | 55,782 | 57,669 | 0 | | 1,253,488 | 6,683 | 142,761 | 526,541 | 577,503 | 0 | |
| Male | 106,749 | 488 | 11,565 | 35,920 | 58,776 | 0 | | 1,016,648 | 3,398 | 125,846 | 301,869 | 585,535 | 0 | |
| Unknown | 290 | 5 | 14 | 79 | 192 | 0 | | 1,743 | 49 | 88 | 494 | 1,112 | 0 | |
| Race | | | | | | | | | | | | | | |
| White | 222,052 | 1,370 | 23,548 | 87,188 | 109,946 | 0 | | 2,155,145 | 9,263 | 259,548 | 788,150 | 1,098,184 | 0 | |
| African American | 5,727 | 36 | 322 | 2,033 | 3,336 | 0 | | 53,585 | 372 | 3,406 | 17,312 | 32,495 | 0 | |
| Other/unknown | 6,495 | 57 | 523 | 2,560 | 3,355 | 0 | | 63,149 | 495 | 5,741 | 23,442 | 33,471 | 0 | |
| Use of Nursing Facilities^c | | | | | | | | | | | | | | |
| Entire year | 193 | 87 | 105 | 0 | 1 | 0 | | 1,947 | 844 | 1,091 | 0 | 12 | 0 | |
| Part year | 440 | 70 | 313 | 51 | 6 | 0 | | 4,288 | 578 | 3,183 | 468 | 59 | 0 | |
| None | 233,641 | 1,306 | 23,975 | 91,730 | 116,630 | 0 | | 2,265,644 | 8,708 | 264,421 | 828,436 | 1,164,079 | 0 | |
| Maintenance Assistance Status | | | | | | | | | | | | | | |
| Cash | 34,737 | 451 | 18,818 | 14,814 | 654 | 0 | | 367,299 | 3,063 | 213,694 | 143,338 | 7,204 | 0 | |
| Medically needy | 1,505 | 135 | 238 | 528 | 604 | 0 | | 12,242 | 772 | 1,546 | 4,337 | 5,587 | 0 | |
| Poverty-related | 104,574 | 593 | 3,284 | 2,243 | 98,454 | 0 | | 1,032,939 | 4,952 | 32,444 | 14,711 | 980,832 | 0 | |
| Other/unknown | 93,458 | 284 | 2,053 | 74,196 | 16,925 | 0 | | 859,399 | 1,343 | 21,011 | 666,518 | 170,527 | 0 | |
| Managed Care (MC) Status | | | | | | | | | | | | | | |
| Fee-for-service (FFS) all year | 234,274 | 1,463 | 24,393 | 91,781 | 116,637 | 0 | | 2,271,879 | 10,130 | 268,695 | 828,904 | 1,164,150 | 0 | |
| FFS part year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | |
| FFS part year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | Percentage with at Least One Rx | Mean Number of Rx | Mean Rx \$ | \$ per Rx | Mean \$, All Medicaid FFS \$ ^c | Rx \$ as a Percentage of All Medicaid FFS \$ ^d | Number of Beneficiaries |
|--|---------------------------------|-------------------|------------|-----------|---|---|-------------------------|
| All | 69.6 % | 10.5 | \$550 | \$55 | \$5,908 | 9.8 % | 234,274 |
| Age | | | | | | | |
| 5 and younger | 65.6 | 3.1 | 143 | 46 | 3,586 | 4.0 | 37,670 |
| 6-14 | 63.5 | 5.4 | 339 | 63 | 5,010 | 6.8 | 53,094 |
| 15-20 | 69.0 | 7.7 | 427 | 55 | 7,009 | 6.1 | 32,991 |
| 21-44 | 73.4 | 12.6 | 677 | 54 | 5,508 | 12.3 | 84,040 |
| 45-64 | 78.3 | 28.6 | 1,598 | 56 | 10,986 | 14.5 | 25,120 |
| 65-74 | 61.1 | 28.8 | 1,464 | 51 | 14,324 | 10.2 | 506 |
| 75-84 | 41.2 | 18.5 | 773 | 42 | 8,001 | 9.7 | 420 |
| 85 and older | 24.3 | 12.4 | 425 | 34 | 5,409 | 7.9 | 432 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 1 |
| Basis of Eligibility^e | | | | | | | |
| Aged | 46.7 | 20.3 | 927 | 46 | 10,118 | 9.2 | 1,463 |
| Disabled | 88.0 | 37.5 | 2,520 | 67 | 21,981 | 11.5 | 24,393 |
| Adults | 71.5 | 10.7 | 495 | 46 | 3,902 | 12.7 | 91,781 |
| Children | 64.6 | 4.6 | 236 | 51 | 4,073 | 5.8 | 116,637 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 |
| Gender | | | | | | | |
| Female | 74.8 | 12.5 | 634 | 51 | 5,709 | 11.1 | 127,235 |
| Male | 63.5 | 8.1 | 516 | 64 | 6,160 | 8.4 | 106,749 |
| Unknown | 29.0 | 1.2 | 72 | 63 | 418 | 17.3 | 290 |
| Race | | | | | | | |
| White | 70.1 | 10.7 | 592 | 55 | 5,998 | 9.9 | 222,052 |
| African American | 56.9 | 5.0 | 262 | 53 | 3,658 | 7.2 | 5,727 |
| Other/unknown | 63.5 | 9.0 | 438 | 49 | 4,820 | 9.1 | 6,495 |
| Use of Nursing Facilities^f | | | | | | | |
| Entire year | 96.9 | 79.8 | 3,605 | 45 | 65,223 | 5.5 | 193 |
| Part year | 98.6 | 81.2 | 4,379 | 54 | 89,741 | 4.9 | 440 |
| None | 69.5 | 10.3 | 570 | 55 | 5,701 | 10.0 | 233,641 |
| Maintenance Assistance Status | | | | | | | |
| Cash | 80.2 | 25.9 | 1,654 | 64 | 13,598 | 12.2 | 34,737 |
| Medically needy | 60.6 | 10.7 | 572 | 53 | 8,467 | 6.8 | 1,505 |
| Poverty related | 64.6 | 5.2 | 274 | 53 | 3,741 | 7.3 | 104,574 |
| Other/unknown | 71.5 | 10.7 | 523 | 49 | 5,434 | 9.6 | 93,458 |

Table ND3

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | Mean Number of Rx | Mean Rx \$ | Rx \$ as a Percentage of | | Number of Rx, Percentage with: | | | | | | Beneficiaries | Mean \$, All Medicaid FFS ^d | Benefit Months |
|--|-------------------|------------|--------------------------|------------------|--------------------------------|----------------------------|----------------------------|-----------------------------|--------------|-------|---------------|--|----------------|
| | | | All Medicaid | FFS ^c | More than 0, but 1 or Less | More than 1, but 2 or Less | More than 2, but 5 or Less | More than 5, but 10 or Less | More than 10 | | | | |
| All | 1.1 | \$60 | 9.8 % | 30.4 % | 49.5 % | 8.1 % | 8.5 % | 2.9 % | 0.6 % | \$609 | 234,274 | 2,271,879 | |
| Age | | | | | | | | | | | | | |
| 5 and younger | 0.3 | 15 | 4.0 | 34.4 | 62.2 | 2.4 | 0.8 | 0.1 | 0.0 | 373 | 37,670 | 361,709 | |
| 6-14 | 0.5 | 33 | 6.8 | 36.5 | 53.9 | 5.0 | 4.2 | 0.5 | 0.0 | 481 | 53,094 | 553,316 | |
| 15-20 | 0.8 | 43 | 6.1 | 31.0 | 53.8 | 8.2 | 6.0 | 1.0 | 0.1 | 711 | 32,991 | 325,132 | |
| 21-44 | 1.3 | 73 | 12.3 | 26.6 | 46.8 | 11.5 | 11.3 | 3.3 | 0.5 | 591 | 84,040 | 783,461 | |
| 45-64 | 3.0 | 168 | 14.5 | 21.7 | 27.0 | 12.0 | 22.6 | 13.3 | 3.4 | 1,154 | 25,120 | 239,043 | |
| 65-74 | 3.3 | 171 | 10.2 | 38.9 | 19.4 | 5.9 | 17.0 | 13.6 | 5.1 | 1,668 | 506 | 4,345 | |
| 75-84 | 2.9 | 121 | 9.7 | 58.8 | 7.9 | 6.2 | 13.3 | 10.7 | 3.1 | 1,248 | 420 | 2,693 | |
| 85 and older | 2.5 | 85 | 7.9 | 75.7 | 3.2 | 1.9 | 8.8 | 6.9 | 3.5 | 1,078 | 432 | 2,168 | |
| Unknown | 0.0 | 0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 1 | 12 | |
| Basis of Eligibility^e | | | | | | | | | | | | | |
| Aged | 2.9 | 134 | 9.2 | 53.3 | 12.9 | 5.6 | 14.1 | 10.3 | 3.8 | 1,461 | 1,463 | 10,130 | |
| Disabled | 3.4 | 229 | 11.5 | 12.0 | 26.8 | 13.0 | 26.9 | 16.8 | 4.5 | 1,996 | 24,393 | 268,695 | |
| Adults | 1.2 | 55 | 12.7 | 28.5 | 46.5 | 11.4 | 10.8 | 2.5 | 0.2 | 432 | 91,781 | 828,904 | |
| Children | 0.5 | 24 | 5.8 | 35.4 | 57.1 | 4.4 | 2.7 | 0.3 | 0.0 | 408 | 116,637 | 1,164,150 | |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | |
| Gender | | | | | | | | | | | | | |
| Female | 1.3 | 64 | 11.1 | 25.2 | 51.3 | 9.5 | 9.6 | 3.7 | 0.8 | 580 | 127,235 | 1,253,488 | |
| Male | 0.9 | 54 | 8.4 | 36.5 | 47.6 | 6.5 | 7.1 | 2.1 | 0.3 | 647 | 106,749 | 1,016,648 | |
| Unknown | 0.2 | 12 | 17.3 | 71.0 | 24.8 | 3.4 | 0.7 | 0.0 | 0.0 | 70 | 290 | 1,743 | |
| Race | | | | | | | | | | | | | |
| White | 1.1 | 61 | 9.9 | 29.9 | 49.7 | 8.2 | 8.7 | 3.0 | 0.6 | 618 | 222,052 | 2,155,145 | |
| African American | 0.5 | 28 | 7.2 | 43.1 | 47.9 | 4.5 | 3.3 | 1.0 | 0.1 | 391 | 5,727 | 53,585 | |
| Other/unknown | 0.9 | 45 | 9.1 | 36.5 | 47.1 | 7.0 | 6.3 | 2.5 | 0.6 | 496 | 6,495 | 63,149 | |
| Use of Nursing Facilities^f | | | | | | | | | | | | | |
| Entire year | 7.9 | 357 | 5.5 | 3.1 | 5.7 | 1.6 | 22.3 | 38.9 | 28.5 | 6,465 | 193 | 1,947 | |
| Part year | 8.3 | 449 | 4.9 | 1.4 | 5.2 | 6.6 | 23.4 | 34.8 | 28.6 | 9,209 | 440 | 4,288 | |
| None | 1.1 | 59 | 10.0 | 30.5 | 49.7 | 8.1 | 8.4 | 2.8 | 0.5 | 588 | 233,641 | 2,265,644 | |
| Maintenance Assistance Status | | | | | | | | | | | | | |
| Cash | 2.5 | 156 | 12.2 | 19.8 | 37.2 | 11.6 | 18.4 | 10.3 | 2.7 | 1,286 | 34,737 | 367,299 | |
| Medically needy | 1.3 | 70 | 6.8 | 39.4 | 39.0 | 6.4 | 7.9 | 5.4 | 1.9 | 1,041 | 1,505 | 12,242 | |
| Poverty related | 0.5 | 28 | 7.3 | 35.4 | 56.2 | 4.3 | 3.1 | 0.8 | 0.1 | 379 | 104,574 | 1,032,939 | |
| Other/unknown | 1.2 | 57 | 9.6 | 28.5 | 46.9 | 11.0 | 10.8 | 2.5 | 0.3 | 591 | 93,458 | 859,399 | |

Table ND4

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
 - d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
 - e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary | All Rx | | | Patented Brand-Name Drugs | | | Off-Patent Brand-Name Drugs | | | Generic Drugs | | |
|--|--------------|-------|-----------|---------------------------|-------|-----------|-----------------------------|-------|-----------|---------------|-------|-----------|
| | Number of Rx | Rx \$ | \$ per Rx | Number of Rx | Rx \$ | \$ per Rx | Number of Rx | Rx \$ | \$ per Rx | Number of Rx | Rx \$ | \$ per Rx |
| All | 1.1 | \$60 | \$55 | 0.5 | \$50 | \$100 | 0.0 | \$2 | \$48 | 0.5 | \$8 | \$15 |
| Age | | | | | | | | | | | | |
| 5 and younger | 0.3 | 15 | 46 | 0.1 | 12 | 89 | 0.0 | 1 | 43 | 0.2 | 2 | 13 |
| 6-14 | 0.5 | 33 | 63 | 0.3 | 28 | 96 | 0.0 | 1 | 79 | 0.2 | 4 | 17 |
| 15-20 | 0.8 | 43 | 55 | 0.4 | 35 | 88 | 0.0 | 2 | 57 | 0.3 | 6 | 17 |
| 21-44 | 1.3 | 73 | 54 | 0.6 | 60 | 103 | 0.0 | 2 | 41 | 0.7 | 11 | 15 |
| 45-64 | 3.0 | 168 | 56 | 1.3 | 139 | 104 | 0.1 | 4 | 44 | 1.6 | 24 | 15 |
| 65-74 | 3.3 | 171 | 51 | 1.4 | 139 | 98 | 0.1 | 6 | 45 | 1.8 | 26 | 14 |
| 75-84 | 2.9 | 121 | 42 | 1.3 | 99 | 79 | 0.1 | 2 | 28 | 1.6 | 19 | 12 |
| 85 and older | 2.5 | 85 | 34 | 0.9 | 63 | 73 | 0.1 | 3 | 29 | 1.5 | 19 | 12 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Basis of Eligibility^d | | | | | | | | | | | | |
| Aged | 2.9 | 134 | 46 | 1.2 | 108 | 89 | 0.1 | 4 | 39 | 1.6 | 21 | 13 |
| Disabled | 3.4 | 229 | 67 | 1.6 | 194 | 121 | 0.1 | 6 | 56 | 1.7 | 29 | 17 |
| Adults | 1.2 | 55 | 46 | 0.5 | 45 | 89 | 0.0 | 2 | 37 | 0.6 | 9 | 14 |
| Children | 0.5 | 24 | 51 | 0.2 | 19 | 84 | 0.0 | 1 | 57 | 0.2 | 3 | 16 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 1.3 | 64 | 51 | 0.6 | 52 | 91 | 0.0 | 2 | 42 | 0.6 | 10 | 15 |
| Male | 0.9 | 54 | 64 | 0.4 | 46 | 115 | 0.0 | 1 | 67 | 0.4 | 7 | 16 |
| Unknown | 0.2 | 12 | 63 | 0.1 | 11 | 104 | 0.0 | 1 | 83 | 0.1 | 1 | 11 |
| Race | | | | | | | | | | | | |
| White | 1.1 | 61 | 55 | 0.5 | 51 | 100 | 0.0 | 2 | 48 | 0.6 | 9 | 15 |
| African American | 0.5 | 28 | 53 | 0.2 | 23 | 101 | 0.0 | 1 | 43 | 0.3 | 4 | 15 |
| Other/unknown | 0.9 | 45 | 49 | 0.4 | 36 | 89 | 0.0 | 2 | 47 | 0.5 | 7 | 15 |
| Use of Nursing Facilities^e | | | | | | | | | | | | |
| Entire year | 7.9 | 357 | 45 | 2.8 | 267 | 94 | 0.3 | 11 | 43 | 4.8 | 77 | 16 |
| Part year | 8.3 | 449 | 54 | 3.2 | 359 | 111 | 0.3 | 10 | 37 | 4.8 | 80 | 17 |
| None | 1.1 | 59 | 55 | 0.5 | 49 | 100 | 0.0 | 2 | 48 | 0.5 | 8 | 15 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 2.5 | 156 | 64 | 1.1 | 131 | 116 | 0.1 | 5 | 52 | 1.2 | 20 | 17 |
| Medically needy | 1.3 | 70 | 53 | 0.6 | 59 | 100 | 0.0 | 1 | 35 | 0.7 | 10 | 15 |
| Poverty related | 0.5 | 28 | 53 | 0.3 | 23 | 89 | 0.0 | 1 | 57 | 0.3 | 4 | 16 |
| Other/unknown | 1.2 | 57 | 49 | 0.5 | 47 | 91 | 0.0 | 2 | 40 | 0.6 | 8 | 14 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Maine, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Therapeutic Category | Number of Rx per Benefit Month Among Users | | | | \$ per Benefit Month Among Users | | | | Users ^e | | | | | | | | |
|---|--|---------------------|-----------------------|---------|----------------------------------|---------------------|-----------------------|---------|--------------------|-------------|-----------------|---------------------------------|--------------------------------------|--------------------------|---------|--------|-----------|
| | Total | Patented Brand-Name | Off-Patent Brand-Name | Generic | Total | Patented Brand-Name | Off-Patent Brand-Name | Generic | Total Number of Rx | Total Rx \$ | Number of Users | Percentage of All Beneficiaries | As a Percentage of All Beneficiaries | Number of Benefit Months | | | |
| | | | | | | | | | | | | | | | | | |
| Anti-infective Agents | 0.2 | 0.1 | 0.0 | 0.1 | \$11 | \$8 | \$0 | \$2 | \$48 | \$88 | \$78 | \$18 | 244,426 | \$11,797,266 | 100,847 | 43.0 % | 1,095,397 |
| Biologicals | 0.3 | 0.2 | 0.0 | 0.0 | 150 | 134 | 6 | 10 | 584 | 552 | 920 | 1,253 | 2,741 | 1,601,317 | 1,014 | 0.4 | 10,649 |
| Antineoplastic Agents | 0.5 | 0.3 | 0.0 | 0.2 | 139 | 130 | 3 | 7 | 306 | 509 | 160 | 36 | 4,911 | 1,501,308 | 1,001 | 0.4 | 10,811 |
| Endocrine/Metabolic Drugs | 0.6 | 0.3 | 0.1 | 0.2 | 23 | 17 | 3 | 4 | 41 | 66 | 27 | 17 | 259,652 | 10,647,608 | 43,039 | 18.4 | 462,204 |
| Cardiovascular Agents | 1.0 | 0.4 | 0.0 | 0.6 | 31 | 24 | 1 | 6 | 32 | 67 | 44 | 10 | 263,028 | 8,444,908 | 25,777 | 11.0 | 274,583 |
| Respiratory Agents | 0.4 | 0.3 | 0.0 | 0.2 | 23 | 20 | 1 | 2 | 52 | 76 | 75 | 15 | 232,251 | 12,109,336 | 48,858 | 20.9 | 535,036 |
| Gastrointestinal Agents | 0.5 | 0.3 | 0.0 | 0.2 | 44 | 40 | 1 | 3 | 88 | 119 | 241 | 19 | 132,857 | 11,716,423 | 24,712 | 10.5 | 265,750 |
| Genitourinary Agents | 0.2 | 0.2 | 0.0 | 0.1 | 11 | 10 | 0 | 1 | 50 | 62 | 45 | 12 | 25,901 | 1,288,214 | 10,830 | 4.6 | 118,924 |
| CNS Drugs | 0.9 | 0.5 | 0.0 | 0.3 | 58 | 52 | 1 | 5 | 66 | 101 | 105 | 14 | 511,955 | 33,930,849 | 55,489 | 23.7 | 588,434 |
| Stimulants/Anti-obesity/Anorexia | 0.7 | 0.5 | 0.0 | 0.2 | 47 | 39 | 2 | 6 | 67 | 79 | 61 | 34 | 82,173 | 5,478,271 | 10,485 | 4.5 | 116,471 |
| Miscellaneous Psychological/Neurological Agents | 0.2 | 0.1 | 0.0 | 0.1 | 21 | 14 | 0 | 7 | 124 | 183 | 0 | 74 | 9,472 | 1,171,977 | 5,116 | 2.2 | 56,017 |
| Analgesics and Anesthetics | 0.5 | 0.1 | 0.0 | 0.4 | 20 | 14 | 0 | 5 | 39 | 144 | 67 | 12 | 342,784 | 13,272,355 | 62,811 | 26.8 | 668,604 |
| Neuromuscular Agents | 0.6 | 0.3 | 0.0 | 0.3 | 40 | 35 | 1 | 5 | 65 | 122 | 50 | 15 | 178,277 | 11,620,747 | 26,681 | 11.4 | 288,090 |
| Nutritional Products | 0.2 | 0.0 | 0.0 | 0.2 | 4 | 0 | 0 | 3 | 17 | 34 | 18 | 16 | 29,371 | 490,259 | 12,820 | 5.5 | 138,759 |
| Hematological Agents | 0.6 | 0.2 | 0.0 | 0.4 | 171 | 165 | 1 | 6 | 302 | 1,044 | 47 | 15 | 20,370 | 6,145,839 | 3,394 | 1.4 | 35,884 |
| Topical Products | 0.2 | 0.1 | 0.0 | 0.1 | 7 | 4 | 0 | 2 | 34 | 62 | 47 | 18 | 109,949 | 3,743,739 | 50,875 | 21.7 | 556,988 |
| Miscellaneous Products | 0.4 | 0.1 | 0.0 | 0.2 | 55 | 35 | 13 | 7 | 147 | 302 | 271 | 35 | 3,237 | 474,528 | 802 | 0.3 | 8,551 |
| Unknown Therapeutic Category | 0.2 | 0.0 | 0.0 | 0.0 | 7 | 0 | 0 | 0 | 43 | 0 | 0 | 0 | 8,102 | 347,425 | 4,812 | 2.1 | 52,688 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 2,461,457 | 135,782,369 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Maine, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Top 10 Drug Groups | Users | | | Among Users | | |
|-------------------------------------|----------------------|-----------------|--------------------------------------|--------------------------|--------------------------------|-------------------|
| | Total Medicaid Rx \$ | Number of Users | As a Percentage of All Beneficiaries | Number of Benefit Months | Number of Rx per Benefit Month | Rx \$ per Benefit |
| | | | | | | \$ per Rx |
| ANTIDEPRESSANTS | \$18,269,084 | 61,913 | 26.4 % | 664,719 | 0.5 | \$58 |
| ANTIPSYCHOTICS | 14,144,310 | 16,223 | 6.9 | 179,529 | 0.6 | 142 |
| ANTICONVULSANT | 10,584,986 | 18,607 | 7.9 | 203,615 | 0.6 | 81 |
| ULCER DRUGS | 9,708,845 | 25,019 | 10.7 | 271,151 | 0.4 | 86 |
| ANTIASTHMATIC | 8,201,175 | 48,526 | 20.7 | 534,165 | 0.3 | 53 |
| ANALGESICS - Narcotic | 7,726,558 | 74,520 | 31.8 | 803,557 | 0.3 | 33 |
| STIMULANTS/ANTI-OBESITY/ANOREXIANTS | 5,478,271 | 13,073 | 5.6 | 147,065 | 0.6 | 67 |
| MISC. HEMATOLOGICAL | 4,744,280 | 782 | 0.3 | 8,178 | 0.6 | 1,009 |
| ANTHYPERLIPIDEMIC | 4,512,429 | 9,165 | 3.9 | 98,612 | 0.6 | 78 |
| ANTIVIRAL | 4,155,680 | 3,496 | 1.5 | 37,876 | 0.3 | 372 |
| Total | 87,525,618 | 271,324 | | 2,948,467 | n.a. | n.a. |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad77847b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | ANTIDEPRESSANTS | | | | | ANTIPSYCHOTICS | | | | | | |
|-----------------------------|------------------------|---------------------|-----------------|-------------------------|--------------------------------------|--------------------------------|----------------------------------|-----------------|-------------------------|--------------------------------------|--------------------------------|----------------------------------|-----------------|-------------------------|--------------------------------------|--------------------------------|----------------------------------|
| | Number of Rx | Rx \$ | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Number of Rx per Benefit Month | Mean Benefit per Rx \$ per Month | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Number of Rx per Benefit Month | Mean Benefit per Rx \$ per Month | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Number of Rx per Benefit Month | Mean Benefit per Rx \$ per Month |
| All | 1,200,721 | \$87,525,618 | 61,913 | 26.4 % | 664,719 | 0.5 | \$28 | 16,223 | 6.9 % | 179,529 | 0.6 | \$79 | | | | | |
| Female | 730,509 | 48,357,860 | 42,829 | 33.7 | 463,960 | 0.5 | 28 | 8,555 | 6.7 | 95,486 | 0.5 | 68 | | | | | |
| Disabled | 300,333 | 23,953,547 | 10,656 | 83.2 | 122,902 | 0.6 | 35 | 4,084 | 31.9 | 47,105 | 0.7 | 93 | | | | | |
| 5 and younger | 866 | 46,403 | 4 | 1.4 | 42 | 0.4 | 17 | 4 | 1.4 | 33 | 0.2 | 10 | | | | | |
| 6-14 | 9,866 | 1,414,893 | 270 | 27.6 | 3,089 | 0.6 | 24 | 202 | 20.7 | 2,365 | 0.6 | 75 | | | | | |
| 15-20 | 11,442 | 924,544 | 479 | 55.0 | 5,488 | 0.6 | 29 | 288 | 33.1 | 3,243 | 0.6 | 79 | | | | | |
| 21-44 | 114,673 | 9,444,383 | 4,636 | 96.9 | 53,718 | 0.6 | 34 | 1,946 | 40.7 | 22,509 | 0.6 | 92 | | | | | |
| 45-64 | 163,486 | 12,123,324 | 5,267 | 89.2 | 60,565 | 0.7 | 38 | 1,644 | 27.9 | 18,955 | 0.7 | 100 | | | | | |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 85 and older | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| Other Eligibles | 430,176 | 24,404,313 | 32,173 | 28.1 | 341,058 | 0.4 | 25 | 4,471 | 3.9 | 48,381 | 0.4 | 44 | | | | | |
| 5 and younger | 8,166 | 392,692 | 23 | 0.1 | 261 | 0.4 | 14 | 27 | 0.2 | 292 | 0.3 | 26 | | | | | |
| 6-14 | 39,905 | 2,447,171 | 1,518 | 6.2 | 17,282 | 0.5 | 24 | 493 | 2.0 | 5,670 | 0.6 | 62 | | | | | |
| 15-20 | 51,964 | 2,927,470 | 4,536 | 28.0 | 49,588 | 0.4 | 22 | 898 | 5.6 | 10,088 | 0.4 | 45 | | | | | |
| 21-44 | 261,138 | 14,180,983 | 21,861 | 46.6 | 232,419 | 0.4 | 25 | 2,567 | 5.5 | 27,501 | 0.3 | 39 | | | | | |
| 45-64 | 62,737 | 4,062,480 | 4,035 | 48.9 | 39,379 | 0.5 | 31 | 405 | 4.9 | 3,987 | 0.4 | 48 | | | | | |
| 65-74 | 3,596 | 240,662 | 115 | 40.8 | 1,285 | 0.6 | 28 | 42 | 14.9 | 466 | 0.6 | 79 | | | | | |
| 75-84 | 1,535 | 94,799 | 40 | 15.9 | 391 | 0.6 | 26 | 27 | 10.8 | 257 | 0.7 | 78 | | | | | |
| 85 and older | 1,135 | 58,056 | 45 | 13.9 | 453 | 0.8 | 36 | 12 | 3.7 | 120 | 0.7 | 69 | | | | | |
| Male | 470,096 | 39,161,116 | 19,075 | 17.9 | 200,701 | 0.5 | 27 | 7,666 | 7.2 | 84,029 | 0.6 | 91 | | | | | |
| Disabled | 186,969 | 18,819,093 | 5,580 | 48.2 | 63,328 | 0.6 | 32 | 3,697 | 32.0 | 42,315 | 0.7 | 112 | | | | | |
| 5 and younger | 2,081 | 321,333 | 15 | 3.0 | 173 | 0.3 | 14 | 15 | 3.0 | 160 | 0.7 | 64 | | | | | |
| 6-14 | 27,702 | 2,181,607 | 761 | 36.0 | 8,744 | 0.6 | 27 | 838 | 39.7 | 9,666 | 0.7 | 89 | | | | | |
| 15-20 | 19,345 | 1,808,089 | 677 | 43.0 | 7,678 | 0.6 | 31 | 587 | 37.3 | 6,754 | 0.7 | 97 | | | | | |
| 21-44 | 62,354 | 7,552,618 | 2,117 | 58.3 | 24,254 | 0.5 | 33 | 1,501 | 41.3 | 17,320 | 0.7 | 122 | | | | | |
| 45-64 | 75,487 | 6,955,446 | 2,010 | 53.6 | 22,479 | 0.6 | 34 | 756 | 20.2 | 8,415 | 0.7 | 128 | | | | | |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 85 and older | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| Other Eligibles | 283,127 | 20,342,023 | 13,495 | 14.2 | 137,373 | 0.4 | 25 | 3,969 | 4.2 | 41,714 | 0.5 | 69 | | | | | |
| 5 and younger | 14,310 | 893,090 | 65 | 0.3 | 768 | 0.3 | 11 | 78 | 0.4 | 884 | 0.4 | 36 | | | | | |
| 6-14 | 79,476 | 6,383,806 | 2,391 | 9.4 | 27,201 | 0.5 | 26 | 1,300 | 5.1 | 14,964 | 0.6 | 80 | | | | | |
| 15-20 | 38,261 | 2,657,859 | 2,146 | 15.0 | 23,450 | 0.4 | 26 | 808 | 5.6 | 8,924 | 0.5 | 83 | | | | | |
| 21-44 | 109,317 | 7,088,263 | 6,850 | 23.9 | 66,488 | 0.4 | 23 | 1,470 | 5.1 | 13,975 | 0.4 | 54 | | | | | |
| 45-64 | 38,118 | 3,019,410 | 1,945 | 27.0 | 18,470 | 0.5 | 27 | 279 | 3.9 | 2,627 | 0.4 | 56 | | | | | |
| 65-74 | 2,066 | 208,952 | 49 | 22.2 | 566 | 0.7 | 31 | 10 | 4.5 | 113 | 0.9 | 94 | | | | | |
| 75-84 | 1,150 | 66,099 | 36 | 21.4 | 330 | 0.6 | 24 | 14 | 8.3 | 149 | 0.6 | 48 | | | | | |
| 85 and older | 429 | 24,544 | 13 | 12.1 | 100 | 0.9 | 22 | 10 | 9.3 | 78 | 0.7 | 47 | | | | | |
| Unknown | 116 | 6,642 | 9 | 3.1 | 58 | 0.5 | 37 | 2 | 0.7 | 14 | 0.7 | 155 | | | | | |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | ANTICONVULSANT | | | | ULCER DRUGS | | | | ANTIASTHMATIC | | | | |
|-----------------------------|-----------------|-------------------------|--------------------------------------|----------------------------------|-----------------|-------------------------|--------------------------------------|----------------------------------|-----------------|-------------------------|--------------------------------------|----------------------------------|-------------|
| | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Mean per Rx \$ per Benefit Month | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Mean per Rx \$ per Benefit Month | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Mean per Rx \$ per Benefit Month | |
| All | 18,607 | 7.9 % | 203,615 | 0.6 | 25,019 | 10.7 % | 271,151 | 0.4 | 48,526 | 20.7 % | 534,165 | 0.3 | \$15 |
| Female | 11,575 | 9.1 | 127,708 | 0.6 | 16,491 | 13.0 | 181,363 | 0.4 | 28,940 | 22.7 | 319,524 | 0.3 | 15 |
| Disabled | 5,077 | 39.6 | 58,551 | 0.8 | 5,649 | 44.1 | 65,451 | 0.5 | 6,960 | 54.3 | 80,261 | 0.4 | 23 |
| 5 and younger | 51 | 18.3 | 596 | 0.6 | 34 | 12.2 | 381 | 0.4 | 94 | 33.7 | 1,066 | 0.2 | 12 |
| 6-14 | 290 | 29.7 | 3,356 | 0.8 | 72 | 7.4 | 819 | 0.5 | 257 | 26.3 | 3,022 | 0.3 | 18 |
| 15-20 | 328 | 37.7 | 3,748 | 0.8 | 171 | 19.6 | 1,995 | 0.4 | 224 | 25.7 | 2,565 | 0.3 | 16 |
| 21-44 | 2,410 | 50.4 | 27,811 | 0.8 | 2,015 | 42.1 | 23,484 | 0.5 | 2,510 | 52.5 | 29,098 | 0.3 | 18 |
| 45-64 | 1,998 | 33.8 | 23,040 | 0.8 | 3,357 | 56.9 | 38,772 | 0.6 | 3,875 | 65.6 | 44,510 | 0.5 | 28 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 6,498 | 5.7 | 69,157 | 0.5 | 10,842 | 9.5 | 115,912 | 0.3 | 21,980 | 19.2 | 239,263 | 0.3 | 13 |
| 5 and younger | 59 | 0.3 | 651 | 0.5 | 382 | 2.1 | 3,609 | 0.3 | 2,667 | 15.0 | 29,317 | 0.2 | 10 |
| 6-14 | 347 | 1.4 | 3,947 | 0.6 | 506 | 2.1 | 5,775 | 0.2 | 4,357 | 17.8 | 49,117 | 0.2 | 13 |
| 15-20 | 814 | 5.0 | 8,873 | 0.5 | 1,337 | 8.3 | 14,635 | 0.2 | 3,255 | 20.1 | 35,865 | 0.2 | 10 |
| 21-44 | 4,412 | 9.4 | 47,233 | 0.5 | 6,598 | 14.1 | 71,439 | 0.3 | 9,570 | 20.4 | 103,765 | 0.3 | 12 |
| 45-64 | 817 | 9.9 | 7,957 | 0.6 | 1,850 | 22.4 | 18,621 | 0.5 | 1,972 | 23.9 | 19,484 | 0.4 | 21 |
| 65-74 | 27 | 9.6 | 288 | 0.8 | 90 | 31.9 | 1,013 | 0.6 | 86 | 30.5 | 975 | 0.5 | 33 |
| 75-84 | 13 | 5.2 | 114 | 0.7 | 47 | 18.7 | 489 | 0.6 | 44 | 17.5 | 460 | 0.7 | 33 |
| 85 and older | 9 | 2.8 | 94 | 0.8 | 32 | 9.9 | 331 | 0.8 | 29 | 9.0 | 280 | 0.4 | 17 |
| Male | 7,027 | 6.6 | 75,874 | 0.6 | 8,524 | 8.0 | 89,769 | 0.4 | 19,575 | 18.3 | 214,562 | 0.3 | 16 |
| Disabled | 3,322 | 28.7 | 38,130 | 0.8 | 2,784 | 24.1 | 31,526 | 0.6 | 3,684 | 31.9 | 42,063 | 0.4 | 24 |
| 5 and younger | 75 | 15.1 | 838 | 0.6 | 59 | 11.8 | 627 | 0.4 | 261 | 52.4 | 3,007 | 0.3 | 17 |
| 6-14 | 530 | 25.1 | 6,137 | 0.7 | 125 | 5.9 | 1,462 | 0.4 | 631 | 29.9 | 7,364 | 0.3 | 17 |
| 15-20 | 392 | 24.9 | 4,546 | 0.8 | 169 | 10.7 | 1,931 | 0.4 | 310 | 19.7 | 3,517 | 0.3 | 12 |
| 21-44 | 1,373 | 37.8 | 15,772 | 0.8 | 970 | 26.7 | 11,133 | 0.5 | 807 | 22.2 | 9,374 | 0.4 | 21 |
| 45-64 | 952 | 25.4 | 10,837 | 0.8 | 1,461 | 39.0 | 16,373 | 0.6 | 1,675 | 44.7 | 18,801 | 0.5 | 31 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 3,705 | 3.9 | 37,744 | 0.5 | 5,740 | 6.0 | 58,243 | 0.4 | 15,891 | 16.7 | 172,499 | 0.3 | 14 |
| 5 and younger | 96 | 0.5 | 1,109 | 0.5 | 478 | 2.5 | 4,647 | 0.3 | 4,293 | 22.6 | 47,218 | 0.2 | 11 |
| 6-14 | 561 | 2.2 | 6,390 | 0.6 | 434 | 1.7 | 4,868 | 0.2 | 5,794 | 22.7 | 65,262 | 0.3 | 14 |
| 15-20 | 475 | 3.3 | 5,094 | 0.6 | 560 | 3.9 | 6,013 | 0.2 | 2,013 | 14.0 | 22,159 | 0.3 | 12 |
| 21-44 | 2,041 | 7.1 | 19,952 | 0.5 | 3,100 | 10.8 | 31,263 | 0.4 | 2,713 | 9.5 | 27,297 | 0.3 | 15 |
| 45-64 | 493 | 6.8 | 4,771 | 0.5 | 1,084 | 15.1 | 10,581 | 0.5 | 972 | 13.5 | 9,393 | 0.4 | 21 |
| 65-74 | 23 | 10.4 | 273 | 0.9 | 44 | 19.9 | 462 | 0.6 | 64 | 29.0 | 712 | 0.5 | 38 |
| 75-84 | 14 | 8.3 | 137 | 0.5 | 25 | 14.9 | 257 | 0.8 | 37 | 22.0 | 410 | 0.4 | 24 |
| 85 and older | 2 | 1.9 | 18 | 1.7 | 15 | 14.0 | 152 | 0.9 | 5 | 4.7 | 48 | 0.3 | 8 |
| Unknown | 5 | 1.7 | 33 | 0.5 | 4 | 1.4 | 19 | 0.6 | 11 | 3.8 | 79 | 0.3 | 10 |

Table ND7B

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a,b,c}
NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | ANALGESICS - Narcotic | | | | | STIMULANTS/ANTI-OBESITY/ANOREXIANTS | | | | | MISC. HEMATOLOGICAL | | | | |
|-----------------------------|-----------------------|-------------------------|--------------------------------------|------------------------------|-------------------------------------|-------------------------------------|-------------------------|--------------------------------------|------------------------------|-------------------------------------|---------------------|-------------------------|--------------------------------------|------------------------------|-------------------------------------|
| | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Mean Rx \$ per Benefit Month | Mean Number of Rx per Benefit Month | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Mean Rx \$ per Benefit Month | Mean Number of Rx per Benefit Month | Number of Users | Users as % of All Benes | Number of Benefit Months Among Users | Mean Rx \$ per Benefit Month | Mean Number of Rx per Benefit Month |
| All | 74,520 | 31.8 % | 803,557 | \$10 | 0.3 | 13,073 | 5.6 % | 147,065 | \$37 | 0.6 | 782 | 0.3 % | 8,178 | \$580 | 0.6 |
| Female | 48,366 | 38.0 | 531,665 | 8 | 0.3 | 4,304 | 3.4 | 48,597 | 34 | 0.5 | 369 | 0.3 | 3,992 | 304 | 0.6 |
| Disabled | 10,495 | 81.9 | 121,349 | 19 | 0.4 | 935 | 7.3 | 10,809 | 37 | 0.5 | 242 | 1.9 | 2,754 | 422 | 0.7 |
| 5 and younger | 21 | 7.5 | 220 | 1 | 0.1 | 8 | 2.9 | 93 | 17 | 0.3 | 0 | 0.0 | 0 | 0 | 0.0 |
| 6-14 | 113 | 11.6 | 1,318 | 2 | 0.1 | 305 | 31.2 | 3,552 | 42 | 0.6 | 1 | 0.1 | 12 | 9.5 | 0.5 |
| 15-20 | 315 | 36.2 | 3,622 | 3 | 0.2 | 144 | 16.5 | 1,645 | 43 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 4,806 | 100.5 | 55,832 | 18 | 0.4 | 288 | 6.0 | 3,326 | 32 | 0.5 | 31 | 0.6 | 355 | 1,032 | 0.7 |
| 45-64 | 5,240 | 88.8 | 60,357 | 21 | 0.5 | 190 | 3.2 | 2,193 | 31 | 0.4 | 210 | 3.6 | 2,387 | 56 | 0.6 |
| 65-74 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 37,871 | 33.1 | 410,316 | 5 | 0.2 | 3,369 | 2.9 | 37,788 | 33 | 0.5 | 127 | 0.1 | 1,238 | 44 | 0.5 |
| 5 and younger | 540 | 3.0 | 6,077 | 1 | 0.1 | 96 | 0.5 | 1,107 | 18 | 0.3 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 1,543 | 6.3 | 17,523 | 1 | 0.1 | 1,733 | 7.1 | 19,702 | 36 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 5,387 | 33.3 | 59,053 | 2 | 0.2 | 618 | 3.8 | 6,921 | 36 | 0.5 | 2 | 0.0 | 15 | 0.3 | 4 |
| 21-44 | 26,716 | 57.0 | 290,541 | 5 | 0.2 | 795 | 1.7 | 8,730 | 27 | 0.4 | 35 | 0.1 | 334 | 0.4 | 36 |
| 45-64 | 3,511 | 42.6 | 35,341 | 11 | 0.3 | 122 | 1.5 | 1,277 | 29 | 0.4 | 65 | 0.8 | 624 | 0.5 | 44 |
| 65-74 | 95 | 33.7 | 1,015 | 10 | 0.4 | 3 | 1.1 | 36 | 11 | 0.3 | 13 | 4.6 | 135 | 0.5 | 55 |
| 75-84 | 38 | 15.1 | 371 | 9 | 0.5 | 1 | 0.4 | 12 | 8 | 1.0 | 9 | 3.6 | 97 | 0.6 | 62 |
| 85 and older | 41 | 12.7 | 395 | 18 | 0.5 | 1 | 0.3 | 3 | 15 | 1.0 | 3 | 0.9 | 33 | 0.7 | 28 |
| Male | 26,143 | 24.5 | 271,807 | 13 | 0.3 | 8,767 | 8.2 | 98,461 | 39 | 0.6 | 413 | 0.4 | 4,186 | 843 | 0.5 |
| Disabled | 5,549 | 48.0 | 62,863 | 29 | 0.4 | 1,845 | 16.0 | 21,175 | 42 | 0.7 | 198 | 1.7 | 2,188 | 935 | 0.6 |
| 5 and younger | 39 | 7.8 | 449 | 1 | 0.1 | 43 | 8.6 | 460 | 16 | 0.4 | 3 | 0.6 | 36 | 1.3 | 5,132 |
| 6-14 | 210 | 9.9 | 2,461 | 1 | 0.1 | 1,083 | 51.3 | 12,463 | 42 | 0.7 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 311 | 19.8 | 3,603 | 2 | 0.1 | 457 | 29.0 | 5,267 | 52 | 0.7 | 2 | 0.1 | 24 | 0.8 | 6,955 |
| 21-44 | 2,309 | 63.6 | 26,152 | 25 | 0.4 | 181 | 5.0 | 2,065 | 34 | 0.6 | 31 | 0.9 | 359 | 0.5 | 3,954 |
| 45-64 | 2,680 | 71.5 | 30,198 | 38 | 0.5 | 81 | 2.2 | 920 | 27 | 0.4 | 162 | 4.3 | 1,769 | 0.5 | 155 |
| 65-74 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 20,594 | 21.6 | 208,944 | 8 | 0.3 | 6,922 | 7.3 | 77,286 | 38 | 0.6 | 215 | 0.2 | 1,998 | 743 | 0.5 |
| 5 and younger | 716 | 3.8 | 8,094 | 1 | 0.1 | 291 | 1.5 | 3,366 | 22 | 0.4 | 7 | 0.0 | 71 | 0.5 | 2,159 |
| 6-14 | 1,529 | 6.0 | 17,343 | 1 | 0.1 | 4,815 | 18.9 | 54,543 | 39 | 0.6 | 7 | 0.0 | 84 | 1.4 | 12,162 |
| 15-20 | 3,033 | 21.1 | 32,139 | 2 | 0.2 | 1,263 | 8.8 | 13,976 | 41 | 0.6 | 1 | 0.0 | 12 | 0.1 | 8 |
| 21-44 | 12,442 | 43.4 | 122,882 | 11 | 0.3 | 471 | 1.6 | 4,582 | 30 | 0.5 | 53 | 0.2 | 494 | 0.5 | 367 |
| 45-64 | 2,770 | 38.5 | 27,432 | 13 | 0.3 | 80 | 1.1 | 795 | 26 | 0.4 | 139 | 1.9 | 1,255 | 0.5 | 50 |
| 65-74 | 46 | 20.8 | 519 | 36 | 0.6 | 1 | 0.5 | 12 | 36 | 0.5 | 4 | 1.8 | 48 | 0.7 | 1,325 |
| 75-84 | 40 | 23.8 | 376 | 16 | 0.5 | 1 | 0.6 | 12 | 13 | 0.1 | 2 | 1.2 | 18 | 0.3 | 31 |
| 85 and older | 18 | 16.8 | 159 | 35 | 0.4 | 0 | 0.0 | 0 | 0 | 0.0 | 2 | 1.9 | 16 | 1.0 | 92 |
| Unknown | 11 | 3.8 | 85 | 1 | 0.2 | 2 | 0.7 | 7 | 22 | 0.3 | 0 | 0.0 | 0 | 0.0 | 0 |

Table ND7C

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | ANTIHYPERTENSIVE | | | | ANTIVIRAL | | | | | |
|-----------------------------|------------------|---------------------------------|--------------------------------------|------------------------------|-----------------|---------------------------------|--------------------------------------|------------------------------|-------------------------|--------------------------|
| | Number of Users | Users as % of All Beneficiaries | Number of Benefit Months Among Users | Mean of Rx per Benefit Month | Number of Users | Users as % of All Beneficiaries | Number of Benefit Months Among Users | Mean of Rx per Benefit Month | Number of Beneficiaries | Number of Benefit Months |
| All | 9,165 | 3.9 % | 98,612 | 0.6 | 3,496 | 1.5 % | 37,876 | 0.3 | 234,274 | 2,271,879 |
| Female | 5,326 | 4.2 | 58,274 | 0.6 | 2,301 | 1.8 | 25,042 | 0.2 | 127,235 | 1,253,488 |
| Disabled | 2,770 | 21.6 | 32,054 | 0.6 | 488 | 3.8 | 5,595 | 0.3 | 12,814 | 142,761 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 3 | 1.1 | 30 | 0.1 | 279 | 2,918 |
| 6-14 | 4 | 0.4 | 41 | 0.4 | 10 | 1.0 | 113 | 0.1 | 977 | 10,844 |
| 15-20 | 5 | 0.6 | 60 | 0.6 | 19 | 2.2 | 212 | 0.2 | 871 | 9,469 |
| 21-44 | 508 | 10.6 | 5,929 | 0.6 | 252 | 5.3 | 2,919 | 0.4 | 4,784 | 53,909 |
| 45-64 | 2,253 | 38.2 | 26,024 | 0.7 | 204 | 3.5 | 2,321 | 0.3 | 5,903 | 65,621 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 |
| Other Eligibles | 2,556 | 2.2 | 26,220 | 0.5 | 1,813 | 1.6 | 19,447 | 0.2 | 114,421 | 1,110,727 |
| 5 and younger | 3 | 0.0 | 31 | 0.1 | 47 | 0.3 | 502 | 0.1 | 17,771 | 170,502 |
| 6-14 | 7 | 0.0 | 84 | 0.4 | 107 | 0.4 | 1,227 | 0.1 | 24,469 | 254,083 |
| 15-20 | 32 | 0.2 | 348 | 0.4 | 250 | 1.5 | 2,613 | 0.2 | 16,174 | 159,062 |
| 21-44 | 1,127 | 2.4 | 12,097 | 0.4 | 1,256 | 2.7 | 13,526 | 0.2 | 46,899 | 448,513 |
| 45-64 | 1,260 | 15.3 | 12,260 | 0.6 | 141 | 1.7 | 1,447 | 0.3 | 8,251 | 72,864 |
| 65-74 | 85 | 30.1 | 965 | 0.7 | 6 | 2.1 | 63 | 0.1 | 282 | 2,504 |
| 75-84 | 34 | 13.5 | 366 | 0.6 | 1 | 0.4 | 11 | 0.1 | 251 | 1,569 |
| 85 and older | 8 | 2.5 | 69 | 0.8 | 5 | 1.5 | 58 | 0.2 | 324 | 1,630 |
| Male | 3,837 | 3.6 | 40,322 | 0.6 | 1,195 | 1.1 | 12,834 | 0.4 | 106,748 | 1,016,636 |
| Disabled | 1,618 | 14.0 | 18,285 | 0.7 | 334 | 2.9 | 3,818 | 0.5 | 11,565 | 125,846 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 6 | 1.2 | 62 | 0.4 | 498 | 5,175 |
| 6-14 | 3 | 0.1 | 34 | 0.3 | 20 | 0.9 | 223 | 0.4 | 79 | 23,627 |
| 15-20 | 7 | 0.4 | 81 | 0.4 | 15 | 1.0 | 180 | 0.3 | 1,574 | 17,300 |
| 21-44 | 361 | 9.9 | 4,203 | 0.6 | 149 | 4.1 | 1,713 | 0.5 | 3,633 | 39,968 |
| 45-64 | 1,247 | 33.3 | 13,967 | 0.7 | 144 | 3.8 | 1,640 | 0.6 | 417 | 39,776 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 |
| Other Eligibles | 2,219 | 2.3 | 22,037 | 0.5 | 861 | 0.9 | 9,016 | 0.4 | 95,183 | 890,790 |
| 5 and younger | 6 | 0.0 | 68 | 0.2 | 50 | 0.3 | 576 | 0.1 | 19,011 | 182,482 |
| 6-14 | 18 | 0.1 | 205 | 0.3 | 117 | 0.5 | 1,283 | 0.2 | 25,473 | 264,392 |
| 15-20 | 28 | 0.2 | 300 | 0.5 | 91 | 0.6 | 983 | 0.2 | 14,345 | 139,122 |
| 21-44 | 983 | 3.4 | 10,095 | 0.5 | 401 | 1.4 | 4,104 | 0.4 | 28,660 | 240,658 |
| 45-64 | 1,118 | 15.5 | 10,622 | 0.6 | 190 | 2.6 | 1,933 | 0.6 | 7,198 | 60,682 |
| 65-74 | 36 | 16.3 | 424 | 0.7 | 7 | 3.2 | 81 | 0.2 | 221 | 1,814 |
| 75-84 | 24 | 14.3 | 269 | 0.7 | 3 | 1.8 | 36 | 0.1 | 168 | 1,114 |
| 85 and older | 6 | 5.6 | 54 | 0.5 | 2 | 1.9 | 20 | 0.1 | 107 | 526 |
| Unknown | 2 | 0.7 | 16 | 0.4 | 0 | 0.0 | 0 | 0.0 | 291 | 1,755 |

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | Rx \$ per Benefit Month | Number of Rx per Benefit Month | Benefit Month | Number of All-Year Nursing Facility Residents | Benefit Months Among All-Year Nursing Facility Residents |
|---|-------------------------|--------------------------------|---------------|---|--|
| All | \$357 | 7.9 | 193 | 1,947 | |
| Age | | | | | |
| 0-64 | 433 | 9.1 | 106 | 1,103 | |
| 65-74 | 361 | 7.4 | 22 | 233 | |
| 75-84 | 235 | 6.3 | 28 | 251 | |
| 85 and older | 208 | 5.8 | 37 | 360 | |
| Unknown | 0 | 0.0 | 0 | 0 | |
| Gender | | | | | |
| Female | 353 | 7.9 | 115 | 1,229 | |
| Male | 365 | 8.0 | 78 | 718 | |
| Unknown | 0 | 0.0 | 0 | 0 | |
| Race | | | | | |
| White | 357 | 8 | 186 | 1,873 | |
| African American | 297 | 4.2 | 2 | 24 | |
| Other/unknown | 384 | 7.9 | 5 | 50 | |
| Basis of Eligibility^c | | | | | |
| Aged | 258 | 6.4 | 87 | 844 | |
| Disabled | 433 | 9.0 | 105 | 1,091 | |
| Adults | 0 | 0.0 | 0 | 0 | |
| Children | 470 | 12.7 | 1 | 12 | |
| Unknown | 0 | 0.0 | 0 | 0 | |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2003 Medicaid enrollment. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e} NONDUAL BENEFICIARIES, MAINE, 2003

| Therapeutic Category | Number of Rx per Benefit Month Among Users | | | \$ per Benefit Month Among Users | | | \$ per Rx | | | Users | | | | | | | |
|---|--|---------------------|-----------------------|----------------------------------|---------------------|-----------------------|-----------|---------------------|-----------------------|--------------------|-------------|-----------------|---|--------------------------|------|--------|-------|
| | Total | Patented Brand-Name | Off-Patent Brand-Name | Total | Patented Brand-Name | Off-Patent Brand-Name | Total | Patented Brand-Name | Off-Patent Brand-Name | Total Number of Rx | Total Rx \$ | Number of Users | Percentage of All-Year Nursing Facility Residents | Number of Benefit Months | | | |
| | Generic | Generic | Generic | Generic | Generic | Generic | Generic | Generic | Generic | As a | | | | | | | |
| Anti-infective Agents | 0.6 | 0.2 | 0.0 | 0.3 | \$26 | \$15 | \$2 | \$9 | \$43 | \$63 | \$61 | \$27 | 887 | \$38,374 | 138 | 71.5 % | 1,469 |
| Biologicals | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Antineoplastic Agents | 0.8 | 0.6 | 0.0 | 0.3 | 261 | 243 | 0 | 18 | 308 | 413 | 0 | 71 | 111 | 34,169 | 13 | 6.7 | 131 |
| Endocrine/Metabolic Drugs | 1.3 | 0.5 | 0.1 | 0.7 | 44 | 30 | 6 | 8 | 33 | 63 | 45 | 10 | 1,207 | 39,288 | 89 | 46.1 | 902 |
| Cardiovascular Agents | 1.8 | 0.3 | 0.1 | 1.5 | 33 | 18 | 2 | 14 | 18 | 58 | 29 | 9 | 2,006 | 36,296 | 113 | 58.5 | 1,090 |
| Respiratory Agents | 0.9 | 0.4 | 0.0 | 0.4 | 39 | 32 | 1 | 7 | 46 | 74 | 38 | 16 | 713 | 32,597 | 76 | 39.4 | 827 |
| Gastrointestinal Agents | 1.2 | 0.6 | 0.0 | 0.6 | 76 | 69 | 0 | 7 | 64 | 111 | 0 | 12 | 1,249 | 79,885 | 104 | 53.9 | 1,051 |
| Genitourinary Agents | 0.8 | 0.5 | 0.0 | 0.2 | 37 | 33 | 2 | 3 | 47 | 61 | 37 | 14 | 358 | 16,992 | 46 | 23.8 | 456 |
| CNS Drugs | 1.8 | 1.0 | 0.0 | 0.9 | 103 | 89 | 1 | 12 | 56 | 93 | 52 | 14 | 2,858 | 159,463 | 150 | 77.7 | 1,550 |
| Stimulants/Anti-obesity/Anorexia | 0.7 | 0.1 | 0.1 | 0.5 | 9 | 4 | 1 | 5 | 13 | 34 | 9 | 9 | 75 | 960 | 11 | 5.7 | 104 |
| Miscellaneous Psychological/Neurological Agents | 0.8 | 0.8 | 0.0 | 0.0 | 102 | 99 | 0 | 3 | 126 | 126 | 0 | 112 | 142 | 17,883 | 17 | 8.8 | 175 |
| Analgesics and Anesthetics | 1.2 | 0.4 | 0.0 | 0.8 | 61 | 49 | 0 | 12 | 49 | 127 | 17 | 14 | 1,426 | 69,534 | 114 | 59.1 | 1,143 |
| Neuromuscular Agents | 2.0 | 0.6 | 0.1 | 1.3 | 113 | 68 | 5 | 40 | 58 | 108 | 76 | 32 | 2,221 | 128,221 | 106 | 54.9 | 1,137 |
| Nutritional Products | 0.8 | 0.0 | 0.1 | 0.8 | 14 | 0 | 1 | 12 | 16 | 8 | 22 | 16 | 373 | 5,968 | 45 | 23.3 | 439 |
| Hematological Agents | 1.7 | 0.1 | 0.1 | 1.5 | 23 | 10 | 1 | 11 | 14 | 138 | 11 | 7 | 965 | 13,092 | 58 | 30.1 | 581 |
| Topical Products | 0.6 | 0.2 | 0.0 | 0.4 | 15 | 8 | 1 | 6 | 26 | 47 | 42 | 16 | 735 | 18,777 | 120 | 62.2 | 1,271 |
| Miscellaneous Products | 0.3 | 0.1 | 0.0 | 0.3 | 5 | 1 | 0 | 3 | 16 | 28 | 0 | 13 | 31 | 484 | 10 | 5.2 | 99 |
| Unknown Therapeutic Category | 0.6 | 0.0 | 0.0 | 0.0 | 59 | 0 | 0 | 0 | 99 | 0 | 0 | 0 | 38 | 3,746 | 6 | 3.1 | 63 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 15,395 | 695,729 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentid=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Table ND9

Nondual Beneficiaries

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

In Maine, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Top 10 Drug Groups in Nursing Facilities | Users | | | | Among Users | | |
|--|----------------------|-----------------|--|--------------------------|--------------------------------|-----------|-------------------------|
| | Total Medicaid Rx \$ | Number of Users | As a Percentage of All-Year Nursing Facility Residents | Number of Benefit Months | Number of Rx per Benefit Month | \$ per Rx | Rx \$ per Benefit Month |
| ANTICONVULSANT | \$88,324 | 97 | 50.3 % | 1,112 | 1.2 | \$64 | \$79 |
| ANTIPSYCHOTICS | 87,579 | 76 | 39.4 | 847 | 1.0 | 107 | 103 |
| ULCER DRUGS | 68,193 | 109 | 56.5 | 1,116 | 0.9 | 69 | 61 |
| ANTIDEPRESSANTS | 63,184 | 143 | 74.1 | 1,483 | 0.9 | 47 | 43 |
| ANALGESICS - Narcotic | 53,897 | 127 | 65.8 | 1,258 | 0.9 | 48 | 43 |
| ANTINEOPLASTICS | 34,169 | 11 | 5.7 | 123 | 0.9 | 308 | 278 |
| ANTIASTHMATIC | 26,381 | 95 | 49.2 | 1,041 | 0.5 | 49 | 25 |
| MUSCULOSKELETAL THERAPY AGENTS | 24,002 | 42 | 21.8 | 475 | 1.2 | 43 | 51 |
| ANTIDIABETIC | 19,235 | 46 | 23.8 | 429 | 1.2 | 38 | 45 |
| MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | 18,194 | 18 | 9.3 | 187 | 0.8 | 123 | 97 |
| Total | 483,158 | 764 | | 8,071 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medspan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | ANTICONVULSANT | | | | | ANTIPSYCHOTICS | | | | |
|-----------------------------|------------------------|------------------|-----------------|---|--------------------------------------|-------------------|-------------|-----------------|---|--------------------------------------|-------------------|--------------|--|--|--|
| | Number of Rx | Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | | | |
| All | 7,501 | \$483,158 | 97 | 50.3 % | 1,112 | 1.2 | \$79 | 76 | 39.4 % | 847 | 1.0 | \$103 | | | |
| Female | 4,798 | 307,316 | 61 | 53.0 | 724 | 1.3 | 77 | 48 | 41.7 | 548 | 1.1 | 108 | | | |
| Disabled | 3,484 | 244,211 | 49 | 77.8 | 588 | 1.3 | 84 | 31 | 49.2 | 357 | 1.1 | 132 | | | |
| 64 or younger | 3,484 | 244,211 | 49 | 77.8 | 588 | 1.3 | 84 | 31 | 49.2 | 357 | 1.1 | 132 | | | |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| 85 and older | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| Other Eligibles | 1,314 | 63,105 | 12 | 23.1 | 136 | 1.0 | 45 | 17 | 32.7 | 191 | 1.0 | 62 | | | |
| 64 or younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| 65-74 | 433 | 23,370 | 5 | 38.5 | 60 | 1.4 | 72 | 4 | 30.8 | 48 | 1.2 | 83 | | | |
| 75-84 | 385 | 17,677 | 4 | 28.6 | 40 | 0.7 | 29 | 8 | 57.1 | 83 | 1.1 | 45 | | | |
| 85 and older | 496 | 22,058 | 3 | 12.0 | 36 | 0.7 | 20 | 5 | 20.0 | 60 | 0.8 | 69 | | | |
| Male | 2,703 | 175,842 | 36 | 46.2 | 388 | 1.2 | 84 | 28 | 35.9 | 299 | 0.8 | 96 | | | |
| Disabled | 1,542 | 97,694 | 20 | 47.6 | 205 | 1.2 | 92 | 12 | 28.6 | 127 | 0.9 | 139 | | | |
| 64 or younger | 1,542 | 97,694 | 20 | 47.6 | 205 | 1.2 | 92 | 12 | 28.6 | 127 | 0.9 | 139 | | | |
| 65-74 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| 75-84 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| 85 and older | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| Other Eligibles | 1,161 | 78,148 | 16 | 44.4 | 183 | 1.1 | 76 | 16 | 44.4 | 172 | 0.7 | 64 | | | |
| 64 or younger | 96 | 4,432 | 2 | 200.0 | 24 | 1.5 | 22 | 0 | 0.0 | 0 | 0.0 | 0 | | | |
| 65-74 | 449 | 34,522 | 9 | 100.0 | 108 | 1.2 | 104 | 3 | 33.3 | 36 | 0.6 | 138 | | | |
| 75-84 | 346 | 19,612 | 5 | 35.7 | 51 | 0.7 | 42 | 6 | 42.9 | 72 | 0.7 | 40 | | | |
| 85 and older | 270 | 19,582 | 0 | 0.0 | 0 | 0.0 | 0 | 7 | 58.3 | 64 | 0.6 | 50 | | | |
| Unknown | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | ULCER DRUGS | | | | | ANTIDEPRESSANTS | | | | | ANALGESICS - Narcotic | | | | |
|-----------------------------|-----------------|---|--------------------------------------|-------------------|------------|-----------------|---|--------------------------------------|-------------------|------------|-----------------------|---|--------------------------------------|-------------------|------------|
| | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ |
| All | 109 | 56.5 % | 1,116 | 0.9 | \$61 | 143 | 74.1 % | 1,483 | 0.9 | \$43 | 127 | 65.8 % | 1,258 | 0.9 | \$43 |
| Female | 61 | 53.0 | 681 | 0.8 | 48 | 88 | 76.5 | 954 | 0.9 | 41 | 75 | 65.2 | 792 | 0.9 | 48 |
| Disabled | 41 | 65.1 | 456 | 0.8 | 52 | 51 | 81.0 | 564 | 1.0 | 44 | 48 | 76.2 | 537 | 1.1 | 64 |
| 64 or younger | 41 | 65.1 | 456 | 0.8 | 52 | 51 | 81.0 | 564 | 1.0 | 44 | 48 | 76.2 | 537 | 1.1 | 64 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 20 | 38.5 | 225 | 0.9 | 38 | 37 | 71.2 | 390 | 0.8 | 38 | 27 | 51.9 | 255 | 0.6 | 14 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 65-74 | 5 | 38.5 | 60 | 1.2 | 52 | 7 | 53.8 | 84 | 1.1 | 53 | 5 | 38.5 | 60 | 0.2 | 4 |
| 75-84 | 7 | 50.0 | 69 | 0.7 | 32 | 10 | 71.4 | 96 | 0.7 | 26 | 6 | 42.9 | 52 | 1.2 | 20 |
| 85 and older | 8 | 32.0 | 96 | 0.8 | 34 | 20 | 80.0 | 210 | 0.7 | 37 | 16 | 64.0 | 143 | 0.5 | 17 |
| Male | 48 | 61.5 | 435 | 1.0 | 82 | 55 | 70.5 | 529 | 0.9 | 45 | 52 | 66.7 | 466 | 0.9 | 34 |
| Disabled | 26 | 61.9 | 235 | 1.0 | 85 | 30 | 71.4 | 280 | 1.1 | 54 | 32 | 76.2 | 307 | 0.8 | 14 |
| 64 or younger | 26 | 61.9 | 235 | 1.0 | 85 | 30 | 71.4 | 280 | 1.1 | 54 | 32 | 76.2 | 307 | 0.8 | 14 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 22 | 61.1 | 200 | 1.1 | 79 | 25 | 69.4 | 249 | 0.8 | 35 | 20 | 55.6 | 159 | 1.0 | 72 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 65-74 | 6 | 66.7 | 50 | 1.0 | 79 | 7 | 77.8 | 84 | 0.8 | 59 | 5 | 55.6 | 49 | 1.0 | 67 |
| 75-84 | 7 | 50.0 | 66 | 1.1 | 89 | 9 | 64.3 | 90 | 0.6 | 28 | 9 | 64.3 | 63 | 1.2 | 43 |
| 85 and older | 9 | 75.0 | 84 | 1.0 | 71 | 9 | 75.0 | 75 | 0.9 | 15 | 6 | 50.0 | 47 | 0.6 | 115 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis.
 - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0ffed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND10B

Nondual Beneficiaries

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | ANTINEOPLASTICS | | | | | ANTIASTHMATIC | | | | | MUSCULOSKELETAL THERAPY AGENTS | | | | |
|-----------------------------|-----------------|---|--------------------------------------|-------------------|--------------|-----------------|---|--------------------------------------|-------------------|-------------|--------------------------------|---|--------------------------------------|-------------------|-------------|
| | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ |
| All | 11 | 5.7 % | 123 | 0.9 | \$278 | 95 | 49.2 % | 1,041 | 0.5 | \$25 | 42 | 21.8 % | 475 | 1.2 | \$51 |
| Female | 9 | 7.8 | 99 | 1.0 | 324 | 55 | 47.8 | 619 | 0.5 | 22 | 25 | 21.7 | 284 | 1.2 | 43 |
| Disabled | 6 | 9.5 | 63 | 1.0 | 460 | 33 | 52.4 | 375 | 0.6 | 26 | 22 | 34.9 | 249 | 1.3 | 49 |
| 64 or younger | 6 | 9.5 | 63 | 1.0 | 460 | 33 | 52.4 | 375 | 0.6 | 26 | 22 | 34.9 | 249 | 1.3 | 49 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 3 | 5.8 | 36 | 0.9 | 87 | 22 | 42.3 | 244 | 0.4 | 15 | 3 | 5.8 | 35 | 0.7 | 7 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 8 | 61.5 | 96 | 0.3 | 12 | 2 | 15.4 | 24 | 0.9 | 9 |
| 75-84 | 1 | 7.1 | 12 | 1.1 | 225 | 6 | 42.9 | 70 | 0.6 | 25 | 1 | 7.1 | 11 | 0.2 | 2 |
| 85 and older | 2 | 8.0 | 24 | 0.8 | 18 | 8 | 32.0 | 78 | 0.3 | 9 | 0 | 0.0 | 0 | 0.0 | 0 |
| Male | 2 | 2.6 | 24 | 0.7 | 86 | 40 | 51.3 | 422 | 0.5 | 31 | 17 | 21.8 | 191 | 1.1 | 61 |
| Disabled | 0 | 0.0 | 0 | 0.0 | 0 | 20 | 47.6 | 206 | 0.5 | 27 | 15 | 35.7 | 167 | 1.2 | 68 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 20 | 47.6 | 206 | 0.5 | 27 | 15 | 35.7 | 167 | 1.2 | 68 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| Other Eligibles | 2 | 5.6 | 24 | 0.6 | 81 | 20 | 55.6 | 216 | 0.6 | 35 | 2 | 5.6 | 24 | 0.5 | 12 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 3 | 300.0 | 36 | 1.5 | 103 | 1 | 100.0 | 12 | 0.7 | 19 |
| 65-74 | 1 | 11.1 | 12 | 0.7 | 94 | 5 | 55.6 | 49 | 0.2 | 8 | 1 | 11.1 | 12 | 0.3 | 4 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 10 | 71.4 | 111 | 0.5 | 30 | 0 | 0.0 | 0 | 0.0 | 0 |
| 85 and older | 1 | 8.3 | 12 | 0.6 | 67 | 2 | 16.7 | 20 | 0.2 | 2 | 0 | 0.0 | 0 | 0.0 | 0 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | ANTIDIABETIC | | | | | MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL | | | | | | |
|-----------------------------|-----------------|---|--------------------------------------|-------------------|-------------|---|---|--------------------------------------|-------------------|-------------|-------------------------------------|--|
| | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | Number of Users | Users as % of All-Year Nursing Facility Residents | Number of Benefit Months Among Users | Mean Number of Rx | Mean Rx \$ | All-Year Nursing Facility Residents | Benefit Months Among All-Year Nursing Facility Residents |
| All | 46 | 23.8 % | 429 | 1.2 | \$45 | 18 | 9.3 % | 187 | 0.8 | \$97 | 193 | 1,947 |
| Female | 22 | 19.1 | 253 | 1.2 | 41 | 13 | 11.3 | 147 | 0.8 | 100 | 115 | 1,229 |
| Disabled | 10 | 15.9 | 111 | 1.4 | 54 | 7 | 11.1 | 84 | 0.8 | 94 | 63 | 694 |
| 64 or younger | 10 | 15.9 | 111 | 1.4 | 54 | 7 | 11.1 | 84 | 0.8 | 94 | 63 | 694 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| Other Eligibles | 12 | 23.1 | 142 | 1.0 | 31 | 6 | 11.5 | 63 | 0.9 | 108 | 52 | 535 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 65-74 | 4 | 30.8 | 48 | 0.9 | 49 | 2 | 15.4 | 24 | 1.1 | 147 | 13 | 136 |
| 75-84 | 2 | 14.3 | 22 | 1.0 | 44 | 2 | 14.3 | 24 | 0.5 | 67 | 14 | 139 |
| 85 and older | 6 | 24.0 | 72 | 1.0 | 14 | 2 | 8.0 | 15 | 0.9 | 111 | 25 | 260 |
| Male | 24 | 30.8 | 176 | 1.2 | 50 | 5 | 6.4 | 40 | 0.7 | 88 | 78 | 718 |
| Disabled | 13 | 31.0 | 58 | 1.5 | 69 | 2 | 4.8 | 13 | 0.4 | 44 | 42 | 397 |
| 64 or younger | 13 | 31.0 | 58 | 1.5 | 69 | 2 | 4.8 | 13 | 0.4 | 44 | 42 | 397 |
| 65-74 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 75-84 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| Other Eligibles | 11 | 30.6 | 118 | 1.0 | 41 | 3 | 8.3 | 27 | 0.9 | 110 | 36 | 321 |
| 64 or younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 |
| 65-74 | 8 | 88.9 | 96 | 1.0 | 48 | 0 | 0.0 | 0 | 0.0 | 0 | 9 | 97 |
| 75-84 | 1 | 7.1 | 2 | 1.0 | 15 | 1 | 7.1 | 12 | 0.1 | 11 | 14 | 112 |
| 85 and older | 2 | 16.7 | 20 | 1.0 | 12 | 2 | 16.7 | 15 | 1.5 | 189 | 12 | 100 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 440 beneficiaries who were in nursing facilities for part of their enrollment and their 4,288 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 MAINE, 2003

| Beneficiary Characteristics | Number of Beneficiaries with at Least One Part D Excluded Rx | | Percentage of Beneficiaries with at Least One Part D Excluded Rx | | Number of Part D Excluded Rx per Beneficiary | Total Number Part D Excluded Rx | | Rx \$ per Beneficiary | Total Part D Excluded Rx \$ | \$ per Part D Excluded Rx | Part D Excluded Rx as a Percentage of Total Number of Beneficiaries | |
|--|--|---------------------------------|--|---------------------------------|--|---------------------------------|--------------------|-----------------------|-----------------------------|---------------------------|---|--|
| | D Excluded Rx | at Least One Part D Excluded Rx | Excluded Rx | at Least One Part D Excluded Rx | | Excluded Rx | All Nondual Rx \$ | | | | 2.7 % | |
| All | 43,587 | 197,274 | 0.8 | 18.6 % | 0.8 | \$16 | \$3,729,182 | \$19 | \$19 | 2.7 % | 234,274 | |
| Age | | | | | | | | | | | | |
| 5 and younger | 3,485 | 7,841 | 0.2 | 9.3 | 8 | 8 | 304,344 | 39 | 39 | 5.7 | 37,670 | |
| 6-14 | 6,172 | 15,484 | 0.3 | 11.6 | 11 | 11 | 559,683 | 36 | 36 | 3.1 | 53,094 | |
| 15-20 | 4,841 | 13,161 | 0.4 | 14.7 | 11 | 11 | 361,636 | 27 | 27 | 2.6 | 32,991 | |
| 21-44 | 20,129 | 96,127 | 1.1 | 24.0 | 18 | 18 | 1,520,223 | 16 | 16 | 2.7 | 84,040 | |
| 45-64 | 8,676 | 62,384 | 2.5 | 34.5 | 38 | 38 | 956,184 | 15 | 15 | 2.4 | 25,120 | |
| 65-74 | 139 | 1,226 | 2.4 | 27.5 | 34 | 34 | 16,970 | 14 | 14 | 2.3 | 506 | |
| 75-84 | 87 | 552 | 1.3 | 20.7 | 14 | 14 | 5,867 | 11 | 11 | 1.8 | 420 | |
| 85 and older | 58 | 499 | 1.2 | 13.4 | 10 | 10 | 4,275 | 9 | 9 | 2.3 | 432 | |
| Unknown | 0 | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 1 | |
| Basis of Eligibility^c | | | | | | | | | | | | |
| Aged | 319 | 2,419 | 1.7 | 21.8 | 19 | 19 | 28,405 | 12 | 12 | 2.1 | 1,463 | |
| Disabled | 10,509 | 87,492 | 3.6 | 43.1 | 75 | 75 | 1,827,619 | 21 | 21 | 3.0 | 24,393 | |
| Adults | 19,937 | 79,392 | 0.9 | 21.7 | 12 | 12 | 1,143,310 | 14 | 14 | 2.5 | 91,781 | |
| Children | 12,822 | 27,971 | 0.2 | 11.0 | 6 | 6 | 729,848 | 26 | 26 | 2.7 | 116,637 | |
| Unknown | 0 | 0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | |
| Gender | | | | | | | | | | | | |
| Female | 29,079 | 136,562 | 1.1 | 22.9 | 19 | 19 | 2,361,258 | 17 | 17 | 2.9 | 127,235 | |
| Male | 14,501 | 60,695 | 0.6 | 13.6 | 13 | 13 | 1,367,217 | 23 | 23 | 2.5 | 106,749 | |
| Unknown | 7 | 17 | 0.1 | 2.4 | 2 | 2 | 707 | 42 | 42 | 3.4 | 290 | |
| Race | | | | | | | | | | | | |
| White | 41,626 | 189,954 | 0.9 | 18.7 | 16 | 16 | 3,594,506 | 19 | 19 | 2.7 | 222,052 | |
| African American | 690 | 2,023 | 0.4 | 12.0 | 7 | 7 | 41,929 | 21 | 21 | 2.8 | 5,727 | |
| Other/unknown | 1,271 | 5,297 | 0.8 | 19.6 | 14 | 14 | 92,747 | 18 | 18 | 3.3 | 6,495 | |
| Use of Nursing Facilities^d | | | | | | | | | | | | |
| Entire year | 120 | 1,532 | 7.9 | 62.2 | 92 | 92 | 17,744 | 12 | 12 | 2.6 | 193 | |
| Part year | 340 | 3,584 | 8.1 | 77.3 | 151 | 151 | 66,362 | 19 | 19 | 3.4 | 440 | |
| None | 43,127 | 192,158 | 0.8 | 18.5 | 16 | 16 | 3,645,076 | 19 | 19 | 2.7 | 233,641 | |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 11,472 | 84,545 | 2.4 | 33.0 | 46 | 46 | 1,613,787 | 19 | 19 | 2.8 | 34,737 | |
| Medically needy | 268 | 1,295 | 0.9 | 17.8 | 12 | 12 | 17,358 | 13 | 13 | 2.0 | 1,505 | |
| Poverty related | 12,255 | 32,782 | 0.3 | 11.7 | 8 | 8 | 824,033 | 25 | 25 | 2.9 | 104,574 | |
| Other/unknown | 19,592 | 78,652 | 0.8 | 21.0 | 14 | 14 | 1,274,004 | 16 | 16 | 2.6 | 93,458 | |

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 MAINE, 2003

| Beneficiary Characteristics | Number Rx per Benefit Month | Rx \$ per Benefit Month | \$ per Rx | Barbiturate \$ per Benefit Month | Benzodiazepine \$ per Benefit Month | Number of Benefit Months |
|--|-----------------------------|-------------------------|-----------|----------------------------------|-------------------------------------|--------------------------|
| All | 0.1 | \$2 | \$19 | \$0 | \$0 | 2,271,879 |
| Age | | | | | | |
| 5 and younger | 0.0 | 1 | 39 | 0 | 0 | 361,709 |
| 6-14 | 0.0 | 1 | 36 | 0 | 0 | 553,316 |
| 15-20 | 0.0 | 1 | 27 | 0 | 0 | 325,132 |
| 21-44 | 0.1 | 2 | 16 | 0 | 1 | 783,461 |
| 45-64 | 0.3 | 4 | 15 | 0 | 1 | 239,043 |
| 65-74 | 0.3 | 4 | 14 | 0 | 1 | 4,345 |
| 75-84 | 0.2 | 2 | 11 | 0 | 0 | 2,693 |
| 85 and older | 0.2 | 2 | 9 | 0 | 1 | 2,168 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 12 |
| Basis of Eligibility^c | | | | | | |
| Aged | 0.2 | 3 | 12 | 0 | 1 | 10,130 |
| Disabled | 0.3 | 7 | 21 | 0 | 2 | 268,695 |
| Adults | 0.1 | 1 | 14 | 0 | 0 | 828,904 |
| Children | 0.0 | 1 | 26 | 0 | 0 | 1,164,150 |
| Unknown | 0.0 | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | |
| Female | 0.1 | 2 | 17 | 0 | 1 | 1,253,488 |
| Male | 0.1 | 1 | 23 | 0 | 0 | 1,016,648 |
| Unknown | 0.0 | 0 | 42 | 0 | 0 | 1,743 |
| Race | | | | | | |
| White | 0.1 | 2 | 19 | 0 | 0 | 2,155,145 |
| African American | 0.0 | 1 | 21 | 0 | 0 | 53,585 |
| Other/unknown | 0.1 | 1 | 18 | 0 | 0 | 63,149 |
| Use of Nursing Facilities^d | | | | | | |
| Entire year | 0.8 | 9 | 12 | 0 | 4 | 1,947 |
| Part year | 0.8 | 15 | 19 | 0 | 4 | 4,288 |
| None | 0.1 | 2 | 19 | 0 | 0 | 2,265,644 |
| Maintenance Assistance Status | | | | | | |
| Cash | 0.2 | 4 | 19 | 0 | 1 | 367,299 |
| Medically needy | 0.1 | 1 | 13 | 0 | 0 | 12,242 |
| Poverty related | 0.0 | 1 | 25 | 0 | 0 | 1,032,939 |
| Other/unknown | 0.1 | 1 | 16 | 0 | 0 | 859,399 |

Table ND12

Nondual Beneficiaries

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
MAINE, 2003

| Drug Category | Number of Users | Rx \$ per User | Total Rx \$ | | Rx \$ as a Percentage of All Part D Excluded Rx \$ | | Total Number Rx. | Number Rx as a Percentage of All Part D Excluded Rx | |
|------------------------------|-----------------|----------------|--------------------|----------------|--|----------------------|------------------|---|--------------|
| | | | Total Rx \$ | Excluded Rx \$ | Excluded Rx % | Part D Excluded Rx % | | | |
| All | 53,872 | \$69 | \$3,729,182 | 100.0 | 100.0 | 197,274 | \$19 | 100.0 | 100.0 |
| Anorexia or weight loss/gain | 170 | 186 | 31,621 | 0.8 | 0.8 | 389 | 81 | 0.2 | 0.2 |
| Fertility drugs | 28 | 23 | 640 | 0.0 | 0.0 | 38 | 17 | 0.0 | 0.0 |
| Drugs for cosmetic purposes | 310 | 13 | 3,952 | 0.1 | 0.1 | 425 | 9 | 0.2 | 0.2 |
| Cough and cold medications | 6,096 | 53 | 325,495 | 8.7 | 8.7 | 9,829 | 33 | 5.0 | 5.0 |
| Vitamins and minerals | 2,090 | 116 | 242,866 | 6.5 | 6.5 | 9,791 | 25 | 5.0 | 5.0 |
| Non-prescription drugs | 24,125 | 71 | 1,708,850 | 45.8 | 45.8 | 61,225 | 28 | 31.0 | 31.0 |
| Barbiturates | 482 | 32 | 15,390 | 0.4 | 0.4 | 3,362 | 5 | 1.7 | 1.7 |
| Benzodiazepines | 17,726 | 56 | 992,967 | 26.6 | 26.6 | 102,097 | 10 | 51.8 | 51.8 |
| Other Part D Excl Rx Drugs | 2,845 | 143 | 407,401 | 10.9 | 10.9 | 10,118 | 40 | 5.1 | 5.1 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2003. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.
- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
 NONDUAL BENEFICIARIES, MAINE, 2003

| Beneficiary Characteristics | Number of Beneficiaries | | | | | Number of Benefit Months | | | | | |
|--|-------------------------|--------------|---------------|---------------|----------------|--------------------------|---------------|----------------|----------------|------------------|----------|
| | All | Aged | Disabled | Adults | Unknown | All | Aged | Disabled | Adults | Unknown | |
| All | 234,274 | 1,463 | 24,393 | 91,781 | 116,637 | 2,271,879 | 10,130 | 268,695 | 828,904 | 1,164,150 | 0 |
| Age | | | | | | | | | | | |
| 5 and younger | 37,670 | 0 | 782 | 0 | 36,888 | 361,709 | 0 | 8,132 | 0 | 353,577 | 0 |
| 6-14 | 53,094 | 0 | 3,091 | 3 | 50,000 | 553,316 | 0 | 34,486 | 22 | 518,808 | 0 |
| 15-20 | 32,991 | 0 | 2,446 | 868 | 29,677 | 325,132 | 0 | 26,778 | 7,158 | 291,196 | 0 |
| 21-44 | 84,040 | 17 | 8,420 | 75,539 | 64 | 783,461 | 136 | 93,893 | 688,927 | 505 | 0 |
| 45-64 | 25,120 | 101 | 9,654 | 15,358 | 7 | 239,043 | 897 | 105,406 | 132,688 | 52 | 0 |
| 65-74 | 506 | 493 | 0 | 13 | 0 | 4,345 | 4,236 | 0 | 109 | 0 | 0 |
| 75-84 | 420 | 420 | 0 | 0 | 0 | 2,693 | 2,693 | 0 | 0 | 0 | 0 |
| 85 and older | 432 | 432 | 0 | 0 | 0 | 2,168 | 2,168 | 0 | 0 | 0 | 0 |
| Unknown | 1 | 0 | 0 | 0 | 1 | 12 | 0 | 0 | 0 | 12 | 0 |
| Gender | | | | | | | | | | | |
| Female | 127,235 | 970 | 12,814 | 55,782 | 57,669 | 1,253,488 | 6,683 | 142,761 | 526,541 | 577,503 | 0 |
| Male | 106,749 | 488 | 11,565 | 35,920 | 58,776 | 1,016,648 | 3,398 | 125,846 | 301,869 | 585,535 | 0 |
| Unknown | 290 | 5 | 14 | 79 | 192 | 1,743 | 49 | 88 | 494 | 1,112 | 0 |
| Race | | | | | | | | | | | |
| White | 222,052 | 1,370 | 23,548 | 87,188 | 109,946 | 2,155,145 | 9,263 | 259,548 | 788,150 | 1,098,184 | 0 |
| African American | 5,727 | 36 | 322 | 2,033 | 3,336 | 53,585 | 372 | 3,406 | 17,312 | 32,495 | 0 |
| Other/unknown | 6,495 | 57 | 523 | 2,560 | 3,355 | 63,149 | 495 | 5,741 | 23,442 | 33,471 | 0 |
| Use of Nursing Facilities^c | | | | | | | | | | | |
| Entire year | 193 | 87 | 105 | 0 | 1 | 1,947 | 844 | 1,091 | 0 | 12 | 0 |
| Part year | 440 | 70 | 313 | 51 | 6 | 4,288 | 578 | 3,183 | 468 | 59 | 0 |
| None | 233,641 | 1,306 | 23,975 | 91,730 | 116,630 | 2,265,644 | 8,708 | 264,421 | 828,436 | 1,164,079 | 0 |
| Maintenance Assistance Status | | | | | | | | | | | |
| Cash | 34,737 | 451 | 18,818 | 14,814 | 654 | 367,299 | 3,063 | 213,694 | 143,338 | 7,204 | 0 |
| Medically needy | 1,505 | 135 | 238 | 528 | 604 | 12,242 | 772 | 1,546 | 4,337 | 5,587 | 0 |
| Poverty related | 104,574 | 593 | 3,284 | 2,243 | 98,454 | 1,032,939 | 4,952 | 32,444 | 14,711 | 980,832 | 0 |
| Other/unknown | 93,458 | 284 | 2,053 | 74,196 | 16,925 | 859,399 | 1,343 | 21,011 | 666,518 | 170,527 | 0 |
| Managed Care (MC) Status | | | | | | | | | | | |
| Fee-for-service (FFS) all year | 234,274 | 1,463 | 24,393 | 91,781 | 116,637 | 2,271,879 | 10,130 | 268,695 | 828,904 | 1,164,150 | 0 |
| FFS part year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FFS part year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MC all year, with Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MC all year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
 - b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
 - c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, MAINE, 2003

| | Beneficiaries and | | |
|--|--|--|--|
| | Benefit Months in Cell J of Table 1 Number of Beneficiaries | Included in Cell K of Table 1 Number of Beneficiaries | Excluded from Cell K of Table 1 Number of Beneficiaries |
| All | 234,274 | 234,274 | 0 |
| Fee-for-service (FFS) all year | 234,274 | 234,274 | 0 |
| FFS part year, with Rx claims | 0 | 0 | 0 |
| FFS part year, with no Rx claims | 0 | 0 | 0 |
| Managed care (MC) all year, with Rx claims | 0 | 0 | 0 |
| MC all year, with no Rx claims | 0 | 0 | 0 |

Source: Data for this table are from the MAX 2003 file for Maine, released by CMS in 07/2007. This table was produced on 11/01/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.